Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAMSES: Ramucirumab + FLOT in resectable esophagogastric adenocarcinoma
NCT02661971Phase 3Completed
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Jun 2016
- Primary completion
- Dec 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of ramucirumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Institut für Klinische Krebsforschung. Started Jun 2016; status: completed.
02
Drugs
ramucirumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT02661971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02661971.